Retatrutide has emerged as a new medication in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By boosting these receptors, Retatrutide controls cravings, {promotesinsulin secretion, and ultimately results in significant slimming. While further inv